INBS Proxy Seeks Approval to Unlock 2.04M Series N-2 Warrants and Add 221,000 Plan Shares
INBS sits 18% above its 52-week low of $1.35 on light trading volume (0.1× avg).
Summary
Intelligent Bio Solutions set its annual meeting for December 3, 2026, asking holders to approve exercise of 2,036,659 Series N-2 Warrants (up to ~$4.7 million in proceeds) and to add 221,000 shares to the 2019 incentive plan.
Key Events · Corporate Governance and Compliance · INBS
-
Nasdaq Vote on Series N-2 Warrants
Proposal 4 asks holders to approve issuance of up to 2,036,659 shares on exercise of the Series N-2 Warrants (strike $2.33) from the September 2, 2026 private placement; those warrants become exercisable only after stockholder approval.
-
Up to $4.7M in Warrant Proceeds at Stake
Full exercise of the Series N-2 Warrants would yield about $4,745,415 gross. If approval fails, the warrants never become exercisable and the company receives nothing.
-
Dilution From Warrant Approval
Approving the warrants would add up to 2,036,659 shares to the 3,316,803 shares outstanding as of the October 13, 2026 record date — roughly 61% dilution on that base — before counting the 12,045,102 shares underlying other outstanding warrants.
-
2019 Plan Reserve Raised 221,000 Shares
Proposal 3 would lift the 2019 Long Term Incentive Plan reserve from 179,500 to 400,500 shares and reset the non-employee director limit to 10,000 shares per fiscal year; only 3,265 shares remain available today.
Analysis · INBS · Industrial Applications And Services
Proposal 4 is the vote that matters. Without stockholder approval under Nasdaq Rule 5635(d), the 2,036,659 Series N-2 Warrants issued in the September 2, 2026 private placement stay locked, and the company cannot collect the roughly $4.7 million their exercise would bring in. Against a going-concern backdrop and a $12.5 million net loss for fiscal 2026, that cash is the difference between funding operations and not. Approval also means up to 2,036,659 new shares hit a base of 3,316,803 outstanding shares — dilution of about 61% on that base — and the investor holding them is already capped at 9.99% ownership. Separately, Proposal 3 adds 221,000 shares to the 2019 Plan, roughly 6.7% of the current share count, with only 3,265 shares left available today. The meeting is set for December 3, 2026, and the company must keep re-soliciting every 60 days until the warrant approval passes.
How filings like this one have moved
In the 30 days to Oct 23, 2026, 29.2% of the 1549 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, INBS was trading at $1.59 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $5.3M. The 52-week trading range was $1.35 to $24.90. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.